Fingolimod, a first-line, once-daily oral disease-modifying therapy for relapsing-remitting multiple sclerosis, has the lowest cost per relapse avoided compared with other first-line agents.
Rashad Carlton, PharmD, MSPH
Advertisement
Articles by Rashad Carlton, PharmD, MSPH
Advertisement
Latest Updated Articles
- Cost-Effectiveness of Fingolimod in Treating Patients With Relapsing-Remitting Multiple Sclerosis
Published: December 12th 2011 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
In the Fragmented Landscape of Long COVID Care, Pharmacists Are Essential
2
Therapeutic Cancer Vaccines: Are We There Yet?
3
Amivantamab Shows 45% Response Rate in Pretreated Head and Neck Cancer: OrigAMI-4 Findings
4
FDA Approves Gazyva for Active Lupus Nephritis
5
